Circle Pharma of South San Francisco, CA, has named David Spellmeyer chief scientific officer. Spellmeyer’s experience includes executive posts at Bay Area biotechs Nodality and Signature BioScience, as well as research work at IBM (NYSE: [[ticker:IBM]]). Circle is developing macrocyclic peptides, drugs that the company says could hit molecular targets that had previously been considered “undruggable” by small molecule or biologic drugs.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
